PLX - Protalix BioTherapeutics, Inc.
| Previous Close | 0.4155 |
| Open | 0.4182 |
| Bid | 0.4100 x 800 |
| Ask | 0.4300 x 900 |
| Day's Range | 0.4150 - 0.4350 |
| 52 Week Range | 0.2700 - 0.8300 |
| Volume | 189,916 |
| Avg. Volume | 591,566 |
| Market Cap | 61.682M |
| Beta (3Y Monthly) | 4.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1800 |
| Earnings Date | Mar 10, 2016 - Mar 14, 2016 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.50 |
- Zacks•last month
Do Options Traders Know Something About Protalix (PLX) Stock We Don't?
Investors need to pay close attention to Protalix (PLX) stock based on the movements in the options market lately.
- GlobeNewswire•last month
Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update
CARMIEL, Israel, March 18, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization.
- ACCESSWIRE•last month
Protalix Biotherapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Protalix Biotherapeutics, Inc. (NYSEMKT: PLX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 18, 2019 ...
- GlobeNewswire•last month
Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference Call
CARMIEL, Israel, March 13, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.
- Simply Wall St.•last month
When Will Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Turn A Profit?
Protalix BioTherapeutics, Inc.'s (NYSEMKT:PLX): Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in IsraelRead More...
- GlobeNewswire•2 months ago
Protalix BioTherapeutics to Hold Full-Year 2018 Financial Results and Corporate Update Conference Call on March 14, 2019
CARMIEL, Israel, March 06, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.
- Benzinga•2 months ago
The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 6) Array Biopharma Inc (NASDAQ: ARRY ) Millendo Therapeutics ...
- GlobeNewswire•2 months ago
Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
CARMIEL, Israel, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that preliminary pharmacokinetic (PK) data from its phase III BRIGHT study of pegunigalsidase alfa, or PRX-102, for the treatment of Fabry disease is the subject of an oral presentation at the 15th Annual WORLDSymposiumTM 2019. The conference is taking place February 4-8, 2019 at the Hyatt Regency Orlando, Orlando, Florida, and the oral presentation is scheduled for Thursday, February 7, 2019 at 8:30 AM ET. PRX-102 is the Company’s plant cell-expressed recombinant, PEGylated, cross-linked α-galactosidase-A drug candidate for the treatment of Fabry disease. The BRIGHT study is a 12-month, open-label switchover study to assess the safety, efficacy and pharmacokinetics of pegunigalsidase alfa 2 mg/kg administered every 4 weeks in up to 30 Fabry patients previously treated with an enzyme replacement therapy (ERT): Fabrazyme® or Replagal®. As of December 23, 2018, 28 patients had been enrolled in the BRIGHT study, and 15 of those patients had completed 9 months of treatment. Samples from these 15 patients underwent pharmacokinetic (PK) evaluation and were tested for the presence of anti-drug antibodies (ADA).
- Benzinga•3 months ago
The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs
The earnings season hasn't panned out well for pharma companies, with Amgen, Inc. (NASDAQ: AMGN ), Novartis AG (NYSE: NVS ) and Illumina, Inc. (NASDAQ: ILMN ) reporting either disappointing results or ...
- GlobeNewswire•3 months ago
New Research: Key Drivers of Growth for Voya Financial, Conduent, Milacron, Altair Engineering, Genesis Healthcare, and Protalix BioTherapeutics — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•3 months ago
Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
CARMIEL, Israel, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that the Company will present preliminary pharmacokinetic (PK) data from its phase III BRIGHT study of pegunigalsidase alfa for the treatment of Fabry disease at the 15th Annual WORLDSymposium™ 2019. The conference will take place February 4-8, 2019 at the Hyatt Regency Orlando, Orlando, Florida. Preliminary results of a Phase 3 study,” highlighting PK and safety data will be presented by Mr. Myrl D. Holida, PA, of the University of Iowa Health Care in Iowa City, Iowa, a principal investigator in the Company’s clinical trial of PRX-102 for the treatment of Fabry disease, on Thursday, February 7, 2019 at 8:30 AM ET.
- Simply Wall St.•3 months ago
Does The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Share Price Tend To Follow The Market?
Anyone researching Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there Read More...
- Zacks•3 months ago
Implied Volatility Surging for Protalix (PLX) Stock Options
Protalix (PLX) needs investors to pay close attention to the stock based on moves in the options market lately.
- Zacks•4 months ago
Moving Average Crossover Alert: Protalix BioTherapeutics
Protalix BioTherapeutics, Inc. (PLX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
- GlobeNewswire•4 months ago
Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease
CARMIEL, Israel, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced the completion of enrollment for the BRIDGE phase III clinical trial of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Additionally, the Company provided an update on the enrollment for the BALANCE and BRIGHT phase III clinical trials which, collectively with the BRIDGE study, comprise the phase III clinical development program for PRX-102 for the treatment of Fabry disease. The BRIGHT study is approximately 90% enrolled and the BALANCE study is approximately 70% enrolled.
- Zacks•5 months ago
Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates
Protalix (PLX) delivered earnings and revenue surprises of -150.00% and -91.71%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•5 months ago
Protalix: 3Q Earnings Snapshot
On a per-share basis, the Carmiel, Israel-based company said it had a loss of 10 cents. The drug developer posted revenue of $663,000 in the period. The company's shares closed at 49 cents. A year ago, ...
- GlobeNewswire•5 months ago
Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update
CARMIEL, Israel, Nov. 07, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.
- Zacks•6 months ago
Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know
Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Benzinga•7 months ago
The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) Amarin Corporation plc (NASDAQ: AMRN ) BIOLINERX Ltd/S ...
- Benzinga•7 months ago
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Biotech shares saw further momentum last week, following up on the gains of the previous two weeks. Will the momentum continue in the upcoming week? Here are the catalytic events that could drive the sector. ...
